Effect of donepezil in patients with Alzheimer's disease previously untreated or treated with memantine or nootropic agents in Germany: an observational study

References

• Fratiglioni L, Launer LJ, Andersen K, et al. Incidence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000;54(11 Suppl 5):S10–5
   Google Scholar
• Lobo A, Launer LJ, Fratiglioni L, et al. Prevalence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000;54(11 Suppl 5):S4–9
   Google Scholar
• Francis PT, Palmer AM, Snape M, et al. The cholinergic hypothesis of Alzheimer’s disease: a review of progress. J Neurol Neurosurg Psychiatry 1999;66:137–47
   PubMed Web of Science ®Google Scholar
• Blass J. Pathophysiology of Alzheimer’s syndrome. Neurology 1993;43(Suppl 4):25–38
   Google Scholar
• Bartus RT, Dean RL 3rd, Beer B, et al. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982;217:408–14
   Google Scholar
• Rogers SL, Doody RS, Mohs RC, et al. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Arch Intern Med 1998;158:1021–31
   PubMed Web of Science ®Google Scholar
• Rogers SL, Farlow MR, Doody RS, et al. A 24-week, double- blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease. Donepezil Study Group. Neurology 1998;50:136–45
   PubMed Web of Science ®Google Scholar
• Burns A, Rossor M, Hecker J, et al. The effects of donepezil in Alzheimer’s disease – results from a multinational trial. Dement Geriatr Cogn Disord 1999;10:237–44
   PubMed Web of Science ®Google Scholar
• Mohs RC, Doody RS, Morris JC, et al. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients [published erratum appears in Neurology 2001;57:1942]. Neurology 2001;57:481–8
   PubMed Web of Science ®Google Scholar
• Winblad B, Engedal K, Soininen H, et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001;57:489–95
   PubMed Web of Science ®Google Scholar
• Relkin N, Reichman W, Orazem J, et al. A large, community-based, open-label trial of donepezil in the treatment of Alzheimer’s disease. Dement Geriatr Cogn Disord 2003;16:15–24
   PubMed Web of Science ®Google Scholar
• Boada-Rovira M, Brodaty H, Cras P, et al. Efficacy and safety of donepezil in patients with Alzheimer’s disease: Results of a global, multinational, clinical experience study. Drugs Aging 2004;21:43–53
   Google Scholar
• Hager K, Calabrese P, Frolich L, et al. An observational clinical study of the efficacy and tolerability of donepezil in the treatment of Alzheimer’s disease. Dement Geriatr Cogn Disord 2003;15:189–98
   PubMed Web of Science ®Google Scholar
• Feldman H, Gauthier S, Hecker J, et al. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer’s disease. Neurology 2001;57:613–20
   PubMed Web of Science ®Google Scholar
• Gauthier S, Feldman H, Hecker J, et al. Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer’s disease. Int Psychogeriatr 2002;14:389–404
   PubMed Web of Science ®Google Scholar
• Feldman H, Gauthier S, Hecker J, et al. Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer’s disease and the effect on caregiver burden. J Am Geriatr Soc 2003;51:737–44
   PubMed Web of Science ®Google Scholar
• Gauthier S, Feldman H, Hecker J, et al. Functional, cognitive and behavioral effects of donepezil in patients with moderate Alzheimer’s disease. Curr Med Res Opin 2002;18:347–54
   PubMed Web of Science ®Google Scholar
• Feldman H, Gauthier S, Hecker J, et al. Efficacy and safety of donepezil in patients with more severe Alzheimer’s disease: A subgroup analysis from a randomized, placebo-controlled trial. Int J Geriatr Psychiatry 2005 [in press]
   Google Scholar
• Wimo A, Winblad B, Shah SN, et al. Impact of donepezil treatment for Alzheimer’s disease on caregiver time. Curr Med Res Opin 2004;20:1221–5
   PubMed Web of Science ®Google Scholar
• Wimo A, Winblad B, Engedal K, et al. An economic evaluation of donepezil in mild to moderate Alzheimer’s disease: results of a 1-year, double-blind, randomized trial. Dement Geriatr Cogn Disord 2003;15:44–54
   PubMed Web of Science ®Google Scholar
• Feldman H, Gauthier S, Hecker J, et al. Economic evaluation of donepezil in moderate to severe Alzheimer’s disease. Neurology 2004;63:644–50
   PubMed Web of Science ®Google Scholar
• Kilpatrick GJ, Tilbrook GS. Memantine. Merz. Curr Opin Investig Drugs 2002;3:798–806
   PubMedGoogle Scholar
• Reisberg B, Doody R, Stoffler A, et al. Memantine in moderate-to-severe Alzheimer’s disease. N Engl J Med 2003;348:1333–41
   PubMed Web of Science ®Google Scholar
• Birks J, Grimley EV, Van Dongen M. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev 2002;4:CD003120
   Google Scholar
• Flicker L, Grimley Evans J. Piracetam for dementia or cognitive impairment. Cochrane Database Syst Rev 2001;2:CD001011
   Google Scholar
• Fioravanti M, Flicker L. Nicergoline for dementia and other age associated forms of cognitive impairment. Cochrane Database Syst Rev 2001;4:CD003159
   Google Scholar
• Lopez-Arrieta JM, Birks J. Nimodipine for primary degenerative, mixed and vascular dementia. Cochrane Database Syst Rev 2002;3:CD000147
   Google Scholar
• Burkart M, Heun R, Maier W, et al. Dementia screening in routine clinical practice. A comparative analysis of MMSE, SIDAM and ADAS. Nervenarzt 1998;69:983–90
   Google Scholar
• Burns A, Byrne EJ, Maurer K. Alzheimer’s disease. Lancet 2002;360:163–5
   Google Scholar
• Whitehead A, Perdomo C, Pratt R, et al. Donepezil for the symptomatic treatment of patients with mild to moderate Alzheimer’s disease: a meta-analysis of individual patient data from randomized controlled trials. Int J Geriatr Psychiatry 2004;19:624–33
   PubMed Web of Science ®Google Scholar
• Mack JL, Whitehouse PJ. Quality of Life in Dementia: state of the art – report of the International Working Group for Harmonization of Dementia Drug Guidelines and the Alzheimer’s Society satellite meeting. Alzheimer Dis Assoc Disord 2001;15:69–71
   PubMedGoogle Scholar
• Demers L, Oremus M, Perrault A, et al. Review of outcome measurement instruments in Alzheimer’s disease drug trials: psychometric properties of functional and quality of life scales. J Geriatr Psychiatry Neurol 2000;13:170–80
   PubMed Web of Science ®Google Scholar
• Rogers SL, Friedhoff LT. The Donepezil Study Group. The efficacy and safety of donepezil in patients with Alzheimer’s disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial. Dementia 1996;7:293–303
   Google Scholar
• Birks JS, Harvey R. Donepezil for dementia due to Alzheimer’s disease (Cochrane Review). In: The Cochrane Library, Issue 1, 2004. Chichester, UK: John Wiley & Sons, Ltd
   Google Scholar
• O’Leary M, Brodaty H, et al. The Australian Donepezil Study Group. Effects of donepezil on patient health-related quality of life and caregiver perception in Alzheimer’s disease: preliminary findings from the Australian subset of a global clinical experience study. Neurobiol Aging 2000;21\(Suppl 1):S146 (658)
   Google Scholar
• Pratt RD, Perdomo CA, Surick IW, et al. Donepezil: tolerability and safety in Alzheimer’s disease. Int J Clin Pract 2002;56:710–17
   PubMed Web of Science ®Google Scholar
• Johannsen P, Barcikowska M, Heun R, et al. Donepezil-treated Alzheimer’s disease patients with apparent initial cognitive decline demonstrate significant benefits when therapy is continued: Results from a randomized, placebo-controlled trial. J Neurol 2003;250\(Suppl 2):II/126
   Google Scholar